摘要：目的 探讨非小细胞肺癌(NSCLC)患者血浆D-二聚体检测的临床意义.方法 采用免疫比浊法检测58例非小细胞肺癌患者和19例健康体检者血浆D-二聚体水平,对肺癌患者血浆D-二聚体水平与癌症病理类型以及疾病分期关系进行分析.结果 非小细胞肺癌患者血浆D-二聚体水平[(2.40±2.07)μg/ml]较健康对照组[(0.28±0.09)μg/ml]明显升高(P＜0.01),其升高程度与肺癌临床分期有关,与癌症病理类型、是否咯血无关.78%(45/58)非小细胞肺癌患者有血浆D-二聚体水平升高与41%(24/58)患者血清癌胚抗原升高比较差异有统计学意义(P＜0.01).结论 非小细胞肺癌患者血浆D-二聚体水平升高,病情越重患者血浆D-二聚体水平越高,提示非小细胞肺癌患者存在血液高凝状态.因此,可为非小细胞肺癌患者病情判断及是否给予抗凝治疗提供参考. Abstract： Objective To investigate the clinical significance of plasma D-dimer level detection in patients with non-small cell lung cancer(NSCLC). Methods The plasma D-dimer levels of 58 NSCLC patients and 19 healthy controls were detected by immunol-nephelometry.The relationship between plasma D-dimer level and the pathological type,clinical stage of NSCLC patients were analyzed.Results The plasma D-dimer level of NSCLC patients [(2.40±2.07)μg/ml]were significantly higher, compared with the control group[(0.28±0.09)μg/ml],P＜0.01, and the plasma D-dimer level had positive correlation with clinical stage of NSCLC,but had no relation with sex,hemoptysis and pathological type. Conclusions The D-dimer levels of NSCLC patients are higher,and increases in accordance with severity of the disease,which indicated that NSCLC patients have hypercoagulable state.So the plasma D-dimer levels can be useful for evaluating severity of NSCLC.

关键词：非小细胞肺癌 肺癌患者 血浆 二聚体水平 检测 

单位：